Novo Nordisk has released full results of its historic soul clinical testing, confirming that oral semaglutide not only helps manage blood sugar, but also reduces the risk of major heart events in people with type 2 diabetes that also suffer from heart or kidney disease. The conclusions were presented at the annual scientific session of the American College of Cardiology at Chicago and published in the New England Journal of Medicine.

According to test data, oral semaglutide reduced the joint risk of death by 14 percent due to heart attacks, strokes and heart -related causes compared to a placebo. In particular, the study recorded a 26 percent decrease in non-fatal heart attack, 12 percent decrease in non-fatal stroke and 7 percent decline in heart-related deaths. In particular, participants from Asian countries saw a 27 percent decrease in heart risk, indicating even more profit in some population.

Dr. Experts at Mohan’s Diabetes Specialty Center saw the results as an important success. He said, “This is a major step in treating people with type 2 diabetes. Oral semaglutide not only helps manage blood sugar, but also protects the heart. It makes an excellent choice for people with high heart risk,” he said.

One of the major takes from the test is that oral semaglutide proved to be effective, whether participants are also taking other common diabetic drugs such as SGLT2 inhibitors. This suggests that the drug can work in combination with existing treatments, providing a more overall approach to diabetes care.

Experts at the GD Hospital and Diabetes Institute in Kolkata echoed Bhavna, stating that oral semaglutide should be considered in the first high -hearted treatment scheme for high -hearted patients. “It is just more than a sugar-lowering medicine. It also helps protect the heart,” he said.

The safety profile of oral semaglutide remained in line with previous studies. The drug showed no new security concern during the test and already used safely worldwide, the clinical data represents more than 33 million patients.

Novo Nordisk has filed for regulatory approval in both the US and Europe to update the labeling of oral semaglutide to reflect its heart benefits. A decision is estimated in 2025.

Representatives of the company said that these results outlines Novo Nordisk’s commitment to address wide spectrum of health issues related to metabolism and heart health. They believe that oral semaglutide type 2 represents a large advancement in providing integrated care for patients with diabetes and heart disease.

With these findings, millions of people living with type 2 diabetes may soon reach the same drug that manages blood sugar, while also reduces the risk of life-threatening heart complications.

Now get the latest news with health and braking news and top headlines worldwide.